Medtronic announced results of a study published in JAMA Network Open that demonstrates a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery and conventional medical management vs. CMM alone.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
